Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial preferentially use the VH1 gene family
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1742-4690
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial preferentially use the VH1 gene family ; volume:9 ; number:2 ; day:13 ; month:9 ; year:2012 ; pages:1 ; date:9.2012
Retrovirology ; 9, Heft 2 (13.9.2012), 1, 9.2012
- Urheber
-
Bonsignori, M.
- Beteiligte Personen und Organisationen
-
Pollara, J.
Moody, MA
Kepler, TB
Chen, X.
Gurley, TC
Kozink, DM
Marshall, DJ
Whitesides, JF
Kaewkungwal, J.
Nitayaphan, S.
Pitisuttithum, P.
Rerks-Ngarm, S.
Kim, JH
Michael, NL
Montefiori, DC
Liao, H.
Ferrari, G.
Haynes, BF
SpringerLink (Online service)
- DOI
-
10.1186/1742-4690-9-S2-P78
- URN
-
urn:nbn:de:1111-2016080727313
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bonsignori, M.
- Pollara, J.
- Moody, MA
- Kepler, TB
- Chen, X.
- Gurley, TC
- Kozink, DM
- Marshall, DJ
- Whitesides, JF
- Kaewkungwal, J.
- Nitayaphan, S.
- Pitisuttithum, P.
- Rerks-Ngarm, S.
- Kim, JH
- Michael, NL
- Montefiori, DC
- Liao, H.
- Ferrari, G.
- Haynes, BF
- SpringerLink (Online service)
Ähnliche Objekte (12)
Critical role for monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity
Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies
Antibodies as carriers of cytotoxicity
The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer
Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
Improved antibody-dependent cell-mediated cytotoxicity (ADCC) of affinity maturated and Fc-engineered antibodies directed against the AML stem cell antigen CD96
Improved Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) of Affinity Maturated and Fc-Engineered Antibodies Directed Against the AML Stem Cell Antigen CD96
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
Correction to: Immunotherapy Utilizing the Combination of Natural Killer– and Antibody Dependent Cellular Cytotoxicity (ADCC)–Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition
Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity
Critical role for monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity
Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies
Antibodies as carriers of cytotoxicity
The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer
Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
Improved antibody-dependent cell-mediated cytotoxicity (ADCC) of affinity maturated and Fc-engineered antibodies directed against the AML stem cell antigen CD96
Improved Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) of Affinity Maturated and Fc-Engineered Antibodies Directed Against the AML Stem Cell Antigen CD96
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
Correction to: Immunotherapy Utilizing the Combination of Natural Killer– and Antibody Dependent Cellular Cytotoxicity (ADCC)–Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition
Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity
Critical role for monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity
Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies
Antibodies as carriers of cytotoxicity
The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer
Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
Improved antibody-dependent cell-mediated cytotoxicity (ADCC) of affinity maturated and Fc-engineered antibodies directed against the AML stem cell antigen CD96
Improved Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) of Affinity Maturated and Fc-Engineered Antibodies Directed Against the AML Stem Cell Antigen CD96
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
Correction to: Immunotherapy Utilizing the Combination of Natural Killer– and Antibody Dependent Cellular Cytotoxicity (ADCC)–Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition